A Pilot Study of the Treatment of Central Serous Chorioretinopathy With Ketoconazole — CSC/Keto  

Chronic Central Serous Chorioretinopathy Clinical Trial

Official title: A Pilot Study of The Treatment of Central Serous Chorioretinopathy With Ketoconazole.

Status Completed

Clinical Trial Summary

The purpose of this study is to determine the effect of an adrenocorticoid antagonist (ketoconazole), 600 mg per day for 4 weeks, in the treatment of patients with central serous chorioretinopathy (CSC).

Clinical Trial Description

A complete ophthalmic evaluation and tests: autofluorescence and Fluorescein angiography, Color Fundus Photography, OCT, including liver and adrenal functions and pregnancy test, if applicable will be done on the screening visit. If the patient is eligible, the patient will be started on ketoconazole 600 mg per day by mouth for the following next 6 weeks. The patient will be rechecked at weeks 5-6, 10,14 and 18. During all these visits a complete ophthalmic examination autofluorescence, OCT, and color fundus photographs will be done.

Repeat Liver and Adrenal function tests will be done at weeks 5-6 and 10 visits.

On the exit visit, all the ophthalmic tests and procedures on the baseline visit will be done. Adverse events, and concomitant medications and treatments will be reported on all visits. ;

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Central Serous Chorioretinopathy
• Chronic Central Serous Chorioretinopathy

• NCT number: NCT00211393
• Study type: Interventional
• Source: Manhattan Eye, Ear & Throat Hospital
• Status: Completed
• Phase: Phase 2
• Start date: May 2005
• Completion date: April 2008